Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish...
Yahoo! Finance: News
Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price
Wedbush raised their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an 'outperform' rating in a report on Wednesday...
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts...
MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Dianthus Therapeutics (DNTH) to Release Earnings on Monday
Dianthus Therapeutics (NASDAQ:DNTH) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-dianthus-therapeutics-inc-stock...
MarketBeat
Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6%
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling...
MarketBeat
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Key Points8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share...
Nasdaq News: Markets
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the fourteen analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have given a buy recomm...
MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High - Should You Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 12-Month High - Still a Buy...